Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Iloperidone
Drug ID BADD_D01134
Description Iloperidone is an atypical antipsychotic for the treatment of schizophrenia symptoms. Hoechst Marion Roussel Inc. researched the drug until May 1996. In June 1997 they gave the research rights to Titan Pharmaceuticals, who gave the worldwide development, manufacturing, and marketing rights to Novartis in August 1998. On June 9, 2004, Titan Pharmaceuticals gave the Phase III development rights to Vanda Pharmaceuticals. FDA approved on May 9, 2009.
Indications and Usage Treatment of acute schizophrenia.
Marketing Status Prescription
ATC Code N05AX14
DrugBank ID DB04946
KEGG ID D02666
MeSH ID C081732
PubChem ID 71360
TTD Drug ID D0M8VE
NDC Product Code 51672-4178; 51672-4181; 43068-112; 43068-108; 43068-902; 43068-106; 51672-4183; 66499-0042; 46016-1332; 43068-104; 66022-0115; 63285-756; 43068-101; 50379-0006; 63285-755; 43068-901; 43068-903; 66499-0067; 51672-4180; 51672-4213; 43068-102; 51672-4179; 51672-4182; 51672-4184; 43068-110; 43068-113
Synonyms iloperidone | Fanapt | HP 873 | HP-873 | Zomaril
Chemical Information
Molecular Formula C24H27FN2O4
CAS Registry Number 133454-47-4
SMILES CC(=O)C1=CC(=C(C=C1)OCCCN2CCC(CC2)C3=NOC4=C3C=CC(=C4)F)OC
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Galactorrhoea05.03.04.002; 21.05.02.0020.000602%Not Available
Gastritis07.08.02.001--
Gastrooesophageal reflux disease07.02.02.003--
Gastrointestinal disorder07.11.01.001--Not Available
Gynaecomastia21.05.04.003; 05.05.02.003--
Haematocrit decreased13.01.05.001--Not Available
Haemoglobin decreased13.01.05.003--Not Available
Hallucination, auditory19.10.02.0030.000903%Not Available
Hiatus hernia22.09.02.004; 07.16.01.001--Not Available
Hostility19.05.01.003--Not Available
Hyperaemia24.03.02.002--Not Available
Hyperchlorhydria07.11.03.001--Not Available
Hypersensitivity10.01.03.0030.001204%
Hyperthermia12.05.01.002; 08.05.01.001--Not Available
Hypokalaemia14.05.03.002--
Hyponatraemia14.05.04.0020.000602%
Hypotension24.06.03.0020.001505%
Hypothyroidism05.02.03.001; 14.11.01.012--
Increased appetite14.03.01.003; 08.01.09.027--Not Available
Infection11.01.08.002--Not Available
Iron deficiency anaemia14.13.02.001; 01.03.01.002--Not Available
Lenticular opacities06.06.01.003--Not Available
Lethargy08.01.01.008; 19.04.04.004; 17.02.04.003--
Leukopenia01.02.02.001--Not Available
Libido decreased21.03.02.005; 19.08.03.001--
Lip pain07.05.03.007--
Lip ulceration07.05.01.006--Not Available
Loss of consciousness17.02.04.0040.001204%Not Available
Mania19.16.02.002--
Menorrhagia21.01.03.002--
The 3th Page    First    Pre   3 4 5 6    Next   Last    Total 6 Pages